BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Lead author of the ATTRibute-CM trial says it was "robustly positive," and shows "the tantalizing possibility of genuine clinical improvements" for this progressive and fatal condition.
With BridgeBio Pharma Inc. expecting to complete a regulatory submission prior to the close of 2023, the 30-month results of ATTRibute-CM provide the most comprehensive overview yet of the benefit-risk profile for acoramidis in ATTR-CM.
PALO ALTO, Calif., Aug. 24, 2023 BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that detailed Phase 3 results.
BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.